|
Getting your Trinity Audio player ready...
|
Aprea Therapeutics (Nasdaq: APRE), a clinical-stage oncology company developing targeted cancer therapies, reported strong third quarter results and highlighted progress in two key drug programs aimed at treating solid tumors and blood cancers driven by genetic mutations.
Aprea is focused on developing precision oncology therapies, targeting cancers with defects in DNA damage repair, p53, WEE1, and ATR pathways. These cancers include colorectal cancer, endometrial cancer, ovarian cancer, pancreatic cancer, lung cancer, as well as blood cancers such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
During the quarter, the company announced promising early data from its WEE1 inhibitor APR-1051, where 3 out of 4 heavily pretreated patients achieved stable disease in a Phase 1 study. The drug is now advancing to a higher dose level as Aprea evaluates its potential across multiple genetically defined tumor types.
Aprea also reached a major milestone with its ATR inhibitor ATRN-119, identifying the recommended Phase 2 dose (RP2D) of 1,100 mg once daily. The company is preparing next-stage studies, including combination trials with radiation therapy and immunotherapy, supported by early signs of synergy in preclinical research.
With $13.7 million in cash and runway into Q4 2026, Aprea is positioned for key catalysts next year, including additional Phase 1 data, dose-expansion decisions, and combination-treatment launches.
In simple terms: Aprea is building next-generation cancer treatments that target the genetic weaknesses inside tumors, aiming for more effective and less toxic therapies for patients.